11c-pe2i
Small moleculeexperimentalImaging agent
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2012 (NCT02319382)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 11-carbon
Oral
No
Parenteral
No
Topical
No
Also known as
- 11c-pe2i
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03675282 | Phase 1/Phase 2 (Phase 2) | Aug 14, 2018 | Cornell University, National Institute of Neurological Disorders and Stroke (NINDS) |
| NCT02319382 | N/A | Jun 1, 2012 | France Parkinson Association, University of Paris |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| France Parkinson Association | Academic/Hospital | 1 | 0 | 1 | 2012 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 0 | 1 | 2018 |
| University of Paris | Academic/Hospital | 1 | 1 | 1 | 2012 |
4 organizations
Page 1 / 1